NZ722505B2 - Pharmaceutical composition for topical administration - Google Patents
Pharmaceutical composition for topical administration Download PDFInfo
- Publication number
- NZ722505B2 NZ722505B2 NZ722505A NZ72250515A NZ722505B2 NZ 722505 B2 NZ722505 B2 NZ 722505B2 NZ 722505 A NZ722505 A NZ 722505A NZ 72250515 A NZ72250515 A NZ 72250515A NZ 722505 B2 NZ722505 B2 NZ 722505B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- pruritus
- composition
- skin
- pharmaceutical composition
- Prior art date
Links
- 238000011200 topical administration Methods 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 102
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 206010061218 Inflammation Diseases 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- 239000002904 solvent Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- 210000004207 dermis Anatomy 0.000 claims description 28
- 210000002615 epidermis Anatomy 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 23
- 208000003251 Pruritus Diseases 0.000 claims description 22
- 230000002500 effect on skin Effects 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000002674 ointment Substances 0.000 claims description 13
- 201000004624 Dermatitis Diseases 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 201000009053 Neurodermatitis Diseases 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 206010037083 Prurigo Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 230000037390 scarring Effects 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 206010041955 Stasis dermatitis Diseases 0.000 claims description 4
- 239000002085 irritant Substances 0.000 claims description 4
- 231100000021 irritant Toxicity 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- 206010012441 Dermatitis bullous Diseases 0.000 claims description 3
- 206010051651 Dermatitis papillaris capillitii Diseases 0.000 claims description 3
- 206010014190 Eczema asteatotic Diseases 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 241001303601 Rosacea Species 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 206010048676 Sjogren-Larsson Syndrome Diseases 0.000 claims description 3
- 206010051446 Transient acantholytic dermatosis Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000009621 actinic keratosis Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 208000024526 cutaneous mucinosis Diseases 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 claims description 3
- 230000036573 scar formation Effects 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 2
- 206010068172 Anal pruritus Diseases 0.000 claims description 2
- 206010071443 Brachioradial pruritus Diseases 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- 206010064190 Cholestatic pruritus Diseases 0.000 claims description 2
- 208000019872 Drug Eruptions Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- 206010024434 Lichen sclerosus Diseases 0.000 claims description 2
- 208000035268 Mast Cell Activation disease Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 235000014150 Myroxylon pereirae Nutrition 0.000 claims description 2
- 244000302151 Myroxylon pereirae Species 0.000 claims description 2
- 102000015439 Phospholipases Human genes 0.000 claims description 2
- 108010064785 Phospholipases Proteins 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 208000009544 Pruritus Ani Diseases 0.000 claims description 2
- 206010063438 Pruritus allergic Diseases 0.000 claims description 2
- 206010039986 Senile pruritus Diseases 0.000 claims description 2
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 2
- 208000021388 Sezary disease Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 206010060875 Uraemic pruritus Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 206010003071 aquagenic pruritus Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 2
- 230000001524 infective effect Effects 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 208000008664 papular urticaria Diseases 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 208000017940 prurigo nodularis Diseases 0.000 claims description 2
- 210000004761 scalp Anatomy 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims 2
- 101001114133 Naja sputatrix Neutral phospholipase A2 muscarinic inhibitor Proteins 0.000 claims 1
- 241000392130 Sphaerium corneum Species 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 15
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract description 10
- 235000019260 propionic acid Nutrition 0.000 abstract description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 65
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 239000012530 fluid Substances 0.000 description 23
- 238000009472 formulation Methods 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 230000035515 penetration Effects 0.000 description 17
- -1 alkaline earth metal salts Chemical class 0.000 description 15
- 239000011521 glass Substances 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000000434 stratum corneum Anatomy 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 102100037611 Lysophospholipase Human genes 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 239000006071 cream Substances 0.000 description 11
- 239000012267 brine Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 10
- 108010058864 Phospholipases A2 Proteins 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000003349 gelling agent Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 7
- MEJYDZQQVZJMPP-UHFFFAOYSA-N 3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound COC1COC2C(OC)COC21 MEJYDZQQVZJMPP-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000011869 Shapiro-Wilk test Methods 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- ALHUZKCOMYUFRB-UHFFFAOYSA-N 3-methylcyclopentadecan-1-one Chemical compound CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- FKUPPRZPSYCDRS-UHFFFAOYSA-N Cyclopentadecanolide Chemical compound O=C1CCCCCCCCCCCCCCO1 FKUPPRZPSYCDRS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100400779 Mus musculus Mdfi gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- OSOIQJGOYGSIMF-UHFFFAOYSA-N cyclopentadecanone Chemical compound O=C1CCCCCCCCCCCCCC1 OSOIQJGOYGSIMF-UHFFFAOYSA-N 0.000 description 2
- 231100000223 dermal penetration Toxicity 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229940072106 hydroxystearate Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000011172 small scale experimental method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003595 thromboxanes Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- 102000001556 1-Phosphatidylinositol 4-Kinase Human genes 0.000 description 1
- 108010029190 1-Phosphatidylinositol 4-Kinase Proteins 0.000 description 1
- AEQXLOUXSHMADM-UHFFFAOYSA-N 1-benzhydrylindole Chemical compound C1=CC2=CC=CC=C2N1C(C=1C=CC=CC=1)C1=CC=CC=C1 AEQXLOUXSHMADM-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- LVOGXJMCDAOKSQ-UHFFFAOYSA-N 10-oxo-10-propan-2-yloxydecanoic acid Chemical compound CC(C)OC(=O)CCCCCCCCC(O)=O LVOGXJMCDAOKSQ-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JMTALIADQVVMJR-UHFFFAOYSA-N 2-bromo-n-chloroaniline Chemical compound ClNC1=CC=CC=C1Br JMTALIADQVVMJR-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HTOJZPHWNDZOPQ-UHFFFAOYSA-N 3-(2-methylpropanoyl)-1-[2-oxo-3-(4-phenoxyphenoxy)propyl]indole-5-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2C(C(=O)C(C)C)=CN1CC(=O)COC(C=C1)=CC=C1OC1=CC=CC=C1 HTOJZPHWNDZOPQ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
- GEDJUAKXFJRZSG-UHFFFAOYSA-N 7-[3-[(3-acetylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound CC(=O)c1cccc(OCc2nn(C)c(C)c2-c2cccc3c(CCCOc4cccc5ccccc45)c([nH]c23)C(O)=O)c1 GEDJUAKXFJRZSG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- AAANJBCQVOQCFQ-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OCCC(C1=C(CCBr)C=CC=C1N1C(C2=CC=CC=C2)C2=CC=CC=C2)=C1Cl Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OCCC(C1=C(CCBr)C=CC=C1N1C(C2=CC=CC=C2)C2=CC=CC=C2)=C1Cl AAANJBCQVOQCFQ-UHFFFAOYSA-N 0.000 description 1
- KTIYNIZXYGFYTF-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OCCC1=C2C(Cl)=C(CCOC3=CC=C(CCC(OC)=O)C=C3)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C2=CC=C1 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OCCC1=C2C(Cl)=C(CCOC3=CC=C(CCC(OC)=O)C=C3)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C2=CC=C1 KTIYNIZXYGFYTF-UHFFFAOYSA-N 0.000 description 1
- 229940124803 CXCR2 antagonist Drugs 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101001005668 Homo sapiens Mastermind-like protein 3 Proteins 0.000 description 1
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 238000001295 Levene's test Methods 0.000 description 1
- 102100025134 Mastermind-like protein 3 Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 description 1
- 231100000233 OECD 428 Skin Absorption: In Vitro Method Toxicity 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000012826 P38 inhibitor Substances 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- KUCRAQDBLZUBQD-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]methanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1C(F)(F)F KUCRAQDBLZUBQD-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- OQROAIRCEOBYJA-UHFFFAOYSA-N bromodiphenylmethane Chemical compound C=1C=CC=CC=1C(Br)C1=CC=CC=C1 OQROAIRCEOBYJA-UHFFFAOYSA-N 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- LXJDKGYSHYYKFJ-UHFFFAOYSA-N cyclohexadecanone Chemical compound O=C1CCCCCCCCCCCCCCC1 LXJDKGYSHYYKFJ-UHFFFAOYSA-N 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 230000010250 cytokine signaling pathway Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- ALOUNLDAKADEEB-UHFFFAOYSA-N dimethyl sebacate Chemical compound COC(=O)CCCCCCCCC(=O)OC ALOUNLDAKADEEB-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical class CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000011016 integrity testing Methods 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001561 neurotransmitter reuptake Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940089513 pentadecalactone Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 125000001874 trioxidanyl group Chemical group [*]OOO[H] 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2- (trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3- yl}ethyl]sulfonyl}phenyl}propanoic acid or pharmaceutically acceptable salts thereof; and to methods of treating inflammation comprising topical administration of a composition comprising a compound of formula I. e salts thereof; and to methods of treating inflammation comprising topical administration of a composition comprising a compound of formula I.
Description
Pharmaceutical ition for topical stration Field of Invention The present invention s to a pharmaceutical composition for topical administration comprising a compound of formula I, 3—{4-[2—{5-chloro-1—(diphenylmethyl)[2-({[2— (trifluoromethyl)benzyl]sulfony|}amino)ethyl]—1H-indol y|]sulfony|}phenyl}propanoic acid or pharmaceutically acceptable salts thereof; and to methods of treating inflammation comprising topical administration of a composition comprising a compound of a I.
Background Cytosolic phospholipase A2 (cPLA2), a member of the phospholipase A2 (PLA2) family, releases arachidonic acid from the olipid membrane and is the rate-limiting enzyme in the biosynthesis of prostaglandins (PGs), thromboxanes (sz) ancl leukotrienes (LTs), all of which are ated in the body's inflammatory se.
Inhibition of this enzyme and other members of the PLA2 family is therefore a potential avenue for the amelioration of inflammatory diseases and conditions (Tibes & Friebe, Phospholipase A2 inhibitors in development. Expert Opin Investig Drugs. 1997 Mar;6(3):279-98).
The compound 3-{4-[2-{5-chloro(diphenylmethyl)—2-[2-({[2- (trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol y|}ethyl]su|fony|}phenyl}propanoic acid was identified as part of an effort to identify novel, high-potency inhibitors of cPLA20c (McKew et al. J Med Chem. 2008 Jun 12):3388—413). It may be ctured as described in W02006/128142, the contents of which are hereby incorporated by reference.
Summary of invention Inflammation of the skin is a symptom of many dermal diseases and conditions. Such conditions e, for e, atopic dermatitis, bullous disorders, collagenoses, psoriasis, psoriatic lesions, seborrheic dermatitis or contact dermatitis, eczema, urticaria, pruritus, rosacea, prurigo ris, hypertrophic scarring, keloid scar formation, scleroderma, Folliculitis keloidalis nuchae, Kawasaki Disease, Sjogren-Larsson Syndrome, Grover's disease, first, second, third and fourth degree burns, cutaneous mucinosis, solar keratosis, squamous cell carcinoma and melanoma. Treatment of inflammation in these conditions by agents targeting the PLA2 family is desirable.
Previously researchers have investigated inflammation treatments targeting the PLA2 family via the oral and ary routes. In general, these treatments have focused on sing therapeutic agents for the oral route, which s good oral ilability and long serum ife when targeting PLA2 to treat inflammation. While still a design requirement, the potency of the agent is less critical when targeting the oral route since it is straightforward to increase the dose by incorporating more of the agent into the dosage form or by increasing the dosage frequency. Indeed, a common feature of prior art PLA2 tors is their relatively low potency, for e, SB 203347 has been shown to fully inhibit PLA2 activity in acid extracted intact human neutrophil homogenate with an IC50 of 4.7 uM (Marshall et al. J Pharmacol Exp Ther. 1995 Sep;274(3):1254- 62).
In general, the oral route is a suboptimal method to treat diseases of the skin. In ular, systemic administration (via the oral route or ise) carries with it the risk of side effects in tissues unconnected with the condition, for example gastrointestinal irritation and/or toxicity. Furthermore, compounds administered orally are subject to first pass metabolism via the liver. Instead, topical administration would frequently be the route of choice, if it could be achieved. The topical administration of a drug has many advantages in the treatment of a localised condition. Since the drug is made available at the site where it is required, an equivalent concentration of the drug circulating systemically is avoided. This can lessen or eliminate the side effects mentioned above.
Therefore, while cPLAZa inhibitors suitable for oral administration have been developed, there remains a need for effective cPLA20c inhibitors that may be administered topically.
Unfortunately, compounds optimised for oral administration are generally able for topical application, often due to the low potency discussed. For dermal administration, very high potency is required. It is also preferable that compound is cleared from the body quickly when not bound to its target. This set of properties allows the medicine to exert strong action on the skin only, and to avoid unwanted systemic effects.
Although desirable, ation for dermal administration can be complex, since the drug is applied to the skin, classically considered a barrier to entry of xenobiotics. Previous research into topical drugs for application to the skin s that compounds with low molecular weight (<500 daltons) and moderate log P (0-3) are ideal for this use.
Surprisingly, the present inventors have found the compound of the t invention, an inhibitor of cPLA20c ped for oral administration, to be efficacious and well tolerated when red as part of a composition for topical stration. Until now, inhibitors of this class of enzyme have not been demonstrated to be useful via the topical route. This finding is particularly surprising given the relatively high molecular weight daltons) of 2-{5—chloro—1-(dipheny|methy|)—2-[2-({[2- uoromethyl)benzy|]su|fony|}amino)ethy|]-1H-indol y|}ethy|]sulfony|}phenyl}propanoic acid and its high log P.
The compounds of the invention when formulated properly are, surprisingly and unexpectedly, shown to have anti-inflammatory action in an animal skin inflammation model and to penetrate into the deeper layers of human skin.
In the course of ch leading to the present invention, it has been found that the compound of formula I can be applied to the skin as the active component of a topical composition and is available for penetration into the skin. Further, said compound has an anti-inflammatory action.
Therefore, the present invention provides a pharmaceutical composition for topical administration comprising a nd of formula I: 0/ \NH V O YVG / or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable diluent or carrier.
Throughout the present application the compound of Formula (I) is also referred to as Compound I. It should be understood that wherever reference to Compound I is made, the use of a pharmaceutically acceptable salt of the compound is also contemplated.
Pharmaceutically acceptable salts of the compounds of a (I) having an acidic moiety can be formed from c and inorganic bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, or magnesium salts; or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri lower alkylamine, for example ethyl-tert-butyl-, diethyl-, diisopropyl-, y|-, tributyl- or 5 dimethylpropylamine, or a mono-, di-, or trihydroxy lower alkylamine, for example mono-, di— or triethanolamine.
The term "topical administration" relates to the application of a nce directly to a body surface, such as the skin. In particularly preferred ments, the topical administration is epicutaneous, i.e., directly onto the surface of the skin. This may mes be referred to as dermal administration. The composition may be provided in any form le for topical administration, including but not limited to nts, gels, creams, lotions, oil-in-water (o/w) emulsions, water-in-oil (w/o) emulsions, oil in water in oil (o/w/o) emulsions, water in oil in water (w/o/w) emulsions, microemulsions, foams, sprays, mousses, patches, powders, , medicated plasters and the like, using well known techniques and excipients. Preferably the composition is provided in the form of a cream, ointment, lotion or gel. Most preferably the composition is provided in the form of a cream or an ointment.
Particularly preferred itions (which may also be referred to herein as formulations) are described in Tables 3 to 7. The most preferred formulations include, but are not limited to: . Ointment 02 (Table 3) . Ointment 02X (Table 3) . Ointment O4v4 (Table 3) . Ointment O4v4E (Table 3) . Ointment 05v2 (Table 3) . nt O7 (Table 3) . Cream 7PE (Table 5) . Cream 9 (Table 5) . Gel 1V3 (Table 7) . Gel 4V3 (Table 7) . Emulsified Gel 1V2 (Table 7) In preferred embodiments, the compound of formula I or pharmaceutically acceptable salt thereof is present at from about 0.01% to about 10% (w/w). More preferably the compound of formula I or pharmaceutically acceptable salt thereof is present at from about 0.3% to about 3%. In other preferred embodiments the nd of formula I or pharmaceutically acceptable salt thereof is present at about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10% (w/w).
The carrier may be a solvent in which the active component is soluble.
Suitable solvents include, but are not limited to water (about 0 — about 25% w/w); alcohols (about 0 — about 20% w/w) selected from monohydric alcohols having from 1 to 18 carbons, such as methanol, ethanol, propanol, isopropanol, butanol, hexanol, cetyl l, stearyl alcohol, and the like; dihydric and polyhydric alcohols, such as propylene glycol, ol; hexanetriols, such as 1,2,6-hexanetriol, sorbitol, 1,3- butanediol, 2,3— butanediol, etc.; lower alkyl ethers of glycols having from 1 to 6 carbons such as the monomethyl or hyl ether of ethylene or diethylene or propylene or ylene glycol, propylene glycol or dipropylene glycol thyl ethers, diethylene glycol monoethyl ether, ethylene glycol monomethyl ether, etc; polyethylene glycols having molecular weights of from 100 to 8,000, preferably in the range 4,000; esters of aliphatic monobasic and dibasic acids having from 2 to 22 carbons and monohydric alcohols having from 1 to 20 carbons, di- and polyhydric alcohols having from 2 to 20 carbons, and sugar alcohols such as isopropyl myristate, pyl palmitate, myristyl myristate, cetyl stearate, methyl stearate, isopropyl sebacate, methyl sebacate, sucrose monolaurate, sucrose monostearate, and the like. Other suitable ts e mannitol, xylitol, sorbitol and monohydric alcohols having from 1 to 6 carbons in the range of 0-20% (w/w), such as methanol, ethanol, propanol, isopropanol, butanol, or hexanol.
More specifically, the solvent may comprise a non-toxic glycol or glycol ether selected from the group consisting of propylene glycol, butylene glycol, diethylene glycol and diethylene glycol ether. Other preferred solvents e, but are not limited to, l, deionised water, benzyl alcohol, PEG 400, dimethyl bide (Arlasolve dmi), diethylene glycol monoethyl ether (Transcutol P), glycerin (glycerol), isopropyl myristate (IPM), isopropanol opyl l), octyldodecanol, phenoxyethanol, oleyl alcohol, mineral oil (liquid paraffin), ol GTCC (caprylic/capric ceride or medium chain triglycerides), castor oil, isopropyl palmitate (IPP), propylene glycol dicaprylate/dicaprate and apricot kernel oil PEG- 6 esters (Labrafil M1944CS).
The composition may also include a co-solvent, which may be selected from the list of solvents provided above. In particular, the co-solvent is selected from the group comprising of water, mannitol, xylitol, sorbitol and monohydric alcohols having from 1 to 6 carbons in the range of 0-20% (w/w), such as methanol, ethanol, propanol, isopropanol, l, or hexanol; and when r co-solvent is selected from one or more of the group consisting of propylene glycol (in the range 0 — 35% w/w), glycerol (in the range 0 — 10% w/w), hylene glycols such as PEG400 (in the range 0 — 80% w/w) or 0 (or similar molecular weight agents in the class) (in the range 0 — 30% w/w).
Furthermore, two or more different ts may be combined into solvent systems with desirable properties. Examples of suitable solvent systems are provided in Table 1: Table 1. Examples of suitable solvent systems.
Solvent Composition (% w/w) systems 1 85 % PEG—400, 15 % Arlasolve DMI 2 75 % PEG-400, 25 % Transcutol P 3 80 0/o PEG—400, 20 0/o propylene glycol 4 20 % EtOH, 55 0/o PEG-400, 25 % Transcutol P 20 0/o EtOH, 8O % PEG-400 6 20 % water, 55 % PEG-400, 25 % Transcutol P 7 20 % EtOH, 20 0/o water, 2 % benzyl alcohol, 33 % PEG-400, 25 % Transcutol P 8 20 % EtOH, 20 % water, 33 % PEG-400, 25 % Where ition is in the form of an emulsion (oil-in-water (o/w), water-in-oil (w/o) oil in water in oil (o/w/o) and water in oil in water (w/o/w)), the composition may further comprise an emulsifier. This may be included to adjust the size of the droplets of oil in the oil phase, which may have a diameter of up to 200 pm, to a smaller size, typically in the range of 1-50 pm, thereby improving the cosmetic appearance of the composition.
The emulsifier may suitably be a water-in-oil emulsifier, e. g. selected from the group consisting of in-oil emulsifiers such as, for example, polyoxyalkylene C12-20 alkyl ethers, such as polyoxyethylenecetyl ether, yethylene—2-lauryl ether, polyoxyethyleneoleyl ether or polyoxyethylene-2—stearyl ether, polyoxyalkylene alkyl esters, an oleate, sorbitan isostearate, sorbitan sesquioleate, glycerol esters of isostearic acid and adipic acid, yceryldiisostearate and polyglyceryl hexaricinoleate. The emulsifier may suitably be a oil-in-water emulsifier, e.g. selected from the group consisting of oil—in-water emulsifiers such as, for example, polyoxyalkylene C12-20 alkyl ethers and esters, such as polyoxyethylenecetyl ether, polyoxyethylene—20-lauryl ether, yethyleneoleyl ether or polyoxyethylene stearyl ether, polysorbate 20, polysorbate 60, polysorbate 80 and the like.
The composition of the present invention may be ed in accordance with methods well known to the person skilled in the art of pharmaceutical formulation. The amount of the individual ingredients in the ition will, to some extent, depend on the concentration of the active component incorporated n. The amount of active component in the composition may vary widely according to the severity of the condition to be treated, the age and condition of the patient and the discretion of the physician.
In on to the above-mentioned ingredients, the present composition may include one or more additional ingredients such as: 1. other therapeutically active nces applied in the ent of dermal inflammatory conditions, including: a. corticosteroids such as hydrocortisone; b. non-steroidal anti-inflammatories such as lic acid, salicylates, Vitamin D analogues such as calcipotriol ex), immunophilins, p38 kinase inhibitors, calcineurin inhibitors such as Tacrolimus and Pimecrolimus; and cannabinoids; c. vasomodulators such as alpha adrenoreceptor ligands; and d. topical anesthetics such as bupivacaine, chlorprocaine, dibucaine, ketamine and pramoxine. 2. anti-infectives such as: a. topical antibiotics such as clindamycin. b. antifungals c. antivirals Other suitable co-administrants are well known to those d in the art, including but not limited to: 55995)!" Histamine H1 or antagonists Histamine H2 receptor antagonists Histamine H3 receptor antagonists Leukotriene antagonists, including antagonists of LTB4, LTC4, LTD4, and LTE4, for example Montelukast . Phosphodiesterase inhibitors, including PDE3 inhibitors, PDE4 inhibitors, PDE5 inhibitors, PDE7 inhibitors and inhibitors of two or more phosphodiesterases, such as dual PDE3/PDE4 inhibitors 6. neurotransmitter re-uptake inhibitors, in particular fluoxetine, sertraline, paroxetine, ziprasidone 7. 5-Lipoxygenase (5-LO) inhibitors or 5—lipoxygenase activating protein (FLAP) inhibitors 8. 0L1- and ocz—adrenoceptor agonist vasoconstrictor sympathomimetic agents Muscarinic M3 receptor antagonists or anticholinergic agents . Bz-adrenoceptor agonists 11. Dual acting Bz/Mg agents 12.Xanthines, such as theophylline and aminophylline 13. Non-steroidal anti-inflammatories, such as sodium cromoglycate and omil sodium 14. Ketotifen .COX-1 inhibitors (NSAIDs) and COX-2 selective tors 16.0ral, inhaled, intranasal and topical glucocorticosteroids 17. Monoclonal antibodies active t endogenous inflammatory entities 18.Anti-tumor necrosis factor (anti-TNF-oc) agents 19.Adhesion molecule tors including VLA-4 antagonists . Kinin- B1 - and B2 -receptor antagonists 21. Immunosuppressive agents 22. Inhibitors of matrix metalloproteases (MMPs) 23.Tachykinin NK1, NKz and NK3 receptor antagonists 24. Elastase inhibitors . Adenosine A2a receptor ts 26. Inhibitors of urokinase 27.Compounds that act on dopamine receptors, e. 9. D2 agonists 28. Modulators of the NFKb pathway, e. g. IKK inhibitors nts that can be classed as mucolytics or ussive agents .Antibiotics 31. Modulators of cytokine signaling pathways, such as p38 MAP kinase inhibitors, SYK kinase inhibitors or JAK kinase inhibitors 32. Modulators of the prostaglandin pathways, ing inhibitors of H-PDGS and antagonists of DP—1 and CRTH2 agonists of chemokine receptors CXCR1 and CXCR2 34.Antagonists of chemokine receptors CCR3, CCR4 and CCR5 . Inhibitors of cytosolic and e phospholipase A2 (CPLAz and SPLAz) 36. Inhibitors of phosphoinositidekinase, 37. HDAC inhibitors, 38. p38 inhibitors and/or 39. CXCR2 antagonists. 40.Calcineurin inhibitors 41.Anti-interleukin 17 (anti—IL-17) agents 42.Anti-interleukin 4 or (anti-IL4R) agents 43.Anti—interleukin 31 (anti—IL-31) agents The effect the active agent or agents in any formulation may be enhanced by use of agents to enhance dermal penetration. Examples of suitable agents to enhance dermal penetration are disclosed at IntJ Pharm. 2013 Apr 15;447(1-2):12-21 (incorporated herein by reference). Thus, the composition of the present invention may e one or more penetration enhancers. Penetration enhancers include but are not limited to 2-(2- ethoxy)ethanol and dimethyl isosorbide in the range of 5 — 30% (w/w). Other non-limiting examples of penetration enhancers include C8-C22 fatty acids such as isostearic acid, ic acid, and oleic acid; C8-C22 fatty alcohols such as oleyl alcohol and lauryl alcohol; lower alkyl esters of C8-C22 fatty acids such as ethyl oleate, isopropyl myristate, butyl stearate, and methyl laurate; di(|ower)a|ky| esters of C6-C8 diacids such as diisopropyl adipate; monoglycerides of C8-C22 fatty acids such as glyceryl monolaurate; tetrahydrofurfuryl alcohol polyethylene glycol ether; polyethylene ; propylene glycol; 2-(2-ethoxyethoxy)ethanol; diethylene glycol monomethyl ether; alkylaryl ethers of polyethylene oxide; polyethylene oxide thyl ethers; polyethylene oxide dimethyl ; dimethyl sulfoxide; glycerol; ethyl acetate; acetoacetic ester; N-alkylpyrrolidone; terpenes; macrocyclic enhancers such as macrocyclic ketones, for example, 3-methylcyclopentadecanone, oheptadecen-l- one, cyclohexadecanone, and cyclopentadecanone; macrocyclic esters such as pentadecalactone.
The composition of the invention may include water, but it may also be substantially or totally free of water. ably, the water content of the composition is from about 0 to about 80 % (w/w).
The present composition may also comprise other components commonly used in l formulations, including but not limited to antioxidants (e.g. alpha—tocopherol, butylated hydroxytoluene, ted hydroxyanisole), stabilizers, chelating agents, thickeners, softeners, lubricants, preservatives, emollients, pigments, fragrances, skin soothing , skin healing agents and skin conditioning agents such as urea, glycerol, oin or bisabolol.
The composition may also comprise a surfactant or emulsifier including, but not limited to, apricot kernel oil PEG-6 esters (Labrafil M1944CS), ceteareth-12 (Brij C20), caprylocaproyl macrogol—8 glycerides (Labrasol), cetostearyl alcohol, glycerol monostearate, lauroyl ol-6 ides (Labrafil M2130CS), macrogol 15 hydroxystearate, (polyoxyl 15 hydroxystearate), macrogol cetostearyl ether (cetomacrogol 1000), PEG-100 stearate (Myrj $100), polyoxyl 35 castor oil (macrogolglycerol ricinoleate), polyoxyl 40 hydrogenated castor oil, PEG—40 stearate (macrogol stearate, polyoxyl stearate), rbate 60 (Tween 60), polysorbate 80 (Tween 80), Span 60 (sorbitan monostearate), steareth-2 (Brij SZ), th-20 (Brij $20), and stearic acid.
The composition may also include one or more viscosity-increasing agents. Viscosity- increasing agents e, but are not limited to nylpyrrolidone, nylpolypyrrolidone (crospovidone), methyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (hypromellose, HPMC), hydroxyethyl cellulose (HEC), xanthan gum, Carbopol (carbomer), and sodium hyaluronate (hyaluronic acid).
In a particularly preferred embodiment, the ition comprises: (a) The compound of formula I; (b) A solvent; (c) A co-solvent; (d) A penetration enhancer; and (e) Water.
In another aspect there is provided a pharmaceutical composition for topical administration comprising a compound of formula I: O// \N V O ng / 2015/050299 or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable diluent or carrier, for use in therapy.
Preferably, therapy involves topical administration In yet another aspect, there is provided a pharmaceutical composition for topical administration comprising a compound of formula I: O7S\ or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable diluent or carrier, for use in ent of dermal inflammatory diseases or conditions.
Also provided herein is the use of a nd of formula I: O7s\ mp5: or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of dermal inflammatory diseases or conditions The dermal inflammatory disease or condition to be treated is preferably a cytosolic phospholipase ependent or cytosolic olipase A20c-mediated disease or condition.
More preferably, the dermal inflammatory disease or condition is selected from the group sing scarring, dermatitis, a proliferative disease or condition, a mast cell disease or ion, a burn or contact with an allergen and/or an irritant.
Yet more ably, the dermal inflammatory disease or condition is selected from the group comprising atopic dermatitis, bullous disorders, collagenoses, psoriasis, psoriatic lesions, seborrheic dermatitis or contact dermatitis, , urticaria, pruritus, rosacea, prurigo nodularis, rophic scarring, keloid scar formation, scleroderma, Folliculitis keloidalis , Kawasaki Disease, Sjogren-Larsson Syndrome, Grover's disease, a first degree burn, a second degree burn, a third degree burn, a fourth degree burn, cutaneous mucinosis, solar keratosis, squamous cell carcinoma or melanoma, asteatotic eczema, discoid , hand eczema, gravitational/varicose eczema, tous drug eruptions, lichen simplex, lichen sclerosus, lichen planus Irritant, allergic contact dermatitis, photoaIlergic/photoaggravated dermatitis, infective (secondary to bacterial/viral/fungal infection) dermatitis, pruritic diseases including those ated with chronic systemic disorders such as uremic pruritus, cholestatic pruritus, adult kitis, aquadynia, aquagenic pruritus, balsam of Peru, biliary pruritus, brachioradial pruritus, drug-induced pruritus, hydroxyethyl starch-induced pruritus, itchy points, lichen simplex chronicus, neurodermatitis, prion pruritus, prurigo, prurigo pigmentosa, prurigo simplex, pruritus ani, pruritus scroti, us vulvae, puncta pruritica, referred itch, renal pruritus, scalp pruritus, senile pruritus, xerotic eczema, itch associated with HIV infection, T-cell lymphoma, Sezary syndrome and mycosis fungoides.
Most preferably the dermal inflammatory disease or condition is psoriasis or atopic dermatitis.
In another aspect there is provided a method of treating inflammation and/or oedema in a patient in need thereof, the method comprising topical administration of a composition comprising a compound of formula I or a pharmaceutically acceptable salt to the area in need of treatment.
Brief Description of Drawings Figure 1 shows the amount of Compound I (ng) recovered from the donor compartment, e, Stratum corneum, epidermis, dermis and receiver fluid after the final time point (t=48 h) ing the application of solvent systems 881 and $82 to dermatomed human skin. Each point ents the mean level of nd I recovered with the error bars enting the range, n=2-3.
Figure 2 shows the same data as Figure 1, but with the amount recovered from the surface removed for ease of data interpretation.
Figure 3 shows the cumulative amount of Compound I in the receiver compartment per unit area 2) over a 48 h experimental period following the application of the solvent systems F881 and F852. Each point ent the mean level of Compound Ii SD detected in the er fluid across skin from three donors, n=9-10.
Figures 4 and 5 show the in vitro penetration of Compound I from the solvent systems (F881 and F882), across dermatomed abdominal skin from three donors. Each point represents the mean level of Compound I red :r SEM, n=9-10.
Figure 6 shows the change in ear thickness over time (in hours after PMA application) for different doses of Compound I.
Figure 7 shows a comparison of Compound I with other nds.
Examples The present invention will be further understood by reference to the following examples.
Example 1 Manufacture of 3-{4-[2-{5-chloro(diphenylmethyl)[2-({[2- (trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H—indol yl}ethyl]sulfonyl}phenyl}propanoic acid The compound of formula I can be manufactured as described in W02006/128142, the ts of which are hereby incorporated by reference. The following steps are carried out: Step 1: 2—Bromochloroaniline (1.0 eq) was dissolved in CH2CI2 (0.25 M), then triethylamine and trifluoroacetyl anhydride (1.1 eq each) were added. The ing mixture was stirred at room temperature for 1 hour. The solvent was evaporated and the residue was purified by flash chromatography with CH2C|2 as eluent to give the amide in 97% yield. m/z(M-H)' 300.0 Step 2: N-(2-BromochIorophenyI)-2,2,2-trifluoroacetamide (Step 1, 1.0 eq) was mixed with 3-butynol (2.0 eq), orobis(tripheny|phosphine)pa||adium(||) (2.5% eq), triethylamine (3.0 eq), CuI (5% eq) in DMF (0.2 M) in a sealed vessel under N2 and heated to 120 °C for 4 hours. The reaction mixture was then d with ethyl acetate, washed with brine and dried over Na2504. Purification by flash column chromatography with 2% MeOH/CH2CI2 afforded the alkyne in 67% yield. m/z(M-H)' 194.09 Step 3: 2-(5-Chloro-1H-indoIy|)ethano| (step 2, 1.0 eq) ancl imidazole (2.0 eq) were dissolved in DMF (0.3 M) at room ature with stirring before tert- butylchlorodiphenylsilane (1.2 eq) was added. The resulting mixture was stirred overnight at room temperature before it was quenched with a saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was washed with water and brine and dried over Nast4. Purification by flash chromatography with CH2CI2 as eluent afforded the si|y| ether as a brown gum in over 90% yield. m/z(M-H)- 433.0 Step 4: 2-({[tert-Butyl(dipheny|)si|y|]oxy}ethy|)ch|oro-1H-indole (Step 3, 1.0 eq) was dissolved in ether (0.4 M) and the solution was cooled to 0 °C. Oxalyl chloride (1.2 eq) was added to the above cold solution with vigorous ng. The reaction mixture was stirred at 0 °C for 1 hour before EtOH was added, ed by NEt3. The resulting mixture was then diluted with more EtOH before it was poured into water and extracted with EtOAc. The organic phase washed with brine, dried over Nast4, and concentrated to give the ter as yellow solid in 70% yield. m/z(M-H)' 533.0 Step 5: Ethyl [2-({[tert—butyl(diphenyl)silyl]oxy}ethyl)chloro-1H-indol y|](oxo)acetate (Step 4, 1 eq), Ph2CHBr (1.5 eq) and CS2CO3 (1.5 eq) were mixed in dry acetonitrile (0.1 M). The mixture was heated to reflux for 2 hours. The reaction mixture was cooled to room ature, diluted with water and extracted with EtOAc. The organic phase was trated and the e was chromatographed with CH2CI2 as eluent to give the N-benzhydryl indole as an orange gum in 45% yield. m/z(M+H)+ 701.3 Step 6: To a solution of ethyl [1-benzhydryI({[tert-butyl(diphenyl)si|y|]oxy}ethyl) chloro-1H-indoIyl] (oxo)acetate (Step 5, 1 eq) in THF (0.1 M) was added BH3.Me2S (2M in THF) (2 eq). The resulting mixture was heated to reflux overnight under N2. The reaction mixture was cooled to room temperature, then quenched slowly with 1N NaOH, extracted with EtOAc, and washed with brine. Concentration afforded the alcohol in 65% yield. m/z(M+H)+ 645.0 Step 7: To a solution of 2-[1-benzhydry|—2-({[tert-butyl(diphenyl)si|y|]oxy}ethyI) chloro-1H—indolyl]ethanol (Step 6, 1 eq) in CH2CI2 ) was added 1,3- bis(diphenylphosphino)—propane (DPPP, 0.75 eq). The solution was cooled to 0 °C under N2, then CBr4 (1.25 eq) was added. The on temperature was allowed to return to room temperature over 2 h. The solvent was ated, and the residue was ed using a short silica gel column with CH2CI2 as eluent to give the bromide in quantitative yield. m/z(M+H)+ 708.0 Step 8: 1-Benzhydryl(2-bromoethyl)({[tert-butyl(diphenyl)silyl]oxy}ethyl) chloro-1H—indole (Step 7, 1 eq) was mixed with methyl(4-mercaptolphenyl)propionate (1.5 eq) and K2CO3 (1.5 eq) in DMF (0.1 M). The resulting mixture was stirred at room temperature under N2 for 2 h, then diluted with water and extracted with EtOAc. The organic extract was washed with brine, trated, and ed by flash chromatographty (CH2CI2 as eluent) to give the thioether as a brownish gum in 80% yield. m/z(M+H)823.0 Step 9: Methyl 3—[4-({2—[1-benzhydryl—2-({[tert-butyl(dipheny|)si|yl]oxy}ethyl)—5- chloro-1H-indolyl]ethyl}sulfanyl)phenyl]propanoate (Step 8, 1 eq) was dissolved in acetonitrile (0.1 M), then molecular sieves (powder, 4 A,) and 4-methylmorpholine N- oxide (NMO) (4eq) were added under N2. After 5 min, n-Pr4NRuO4 (TPAP) (5% eq) was added. The resulting mixture was heated at 40 °C for 1.5 h. The mixture was concentrated and the residue was purified by flash chromatography with CH2CI2, then 1 % EtOAc/CH2CI2 as eluent to give the sulfone as a white foam in 44% yield. m/z(M+H)+855.1 Step 10: Methyl 3-(4-{2—[1-benzhydryl({[tert-butyl(diphenyl)silyl]oxy}ethyl) chloro-1H-indolyl]ethoxy}phenyl)propanoate (Step 9, 1 eq) was dissolved in THF (0.1 M) and cooled to 0 °C then treated with nBu4NF (1 M in THF) (1.2 eq). The resulting mixture was stirred at 0 °C for 5 min, then warmed to room temperature and stirred for min. The solvent was evaporated and the residue was purified by flash chromatography with EtOAc/CH2CI2 (1:9 to 1:4) as eluent to give the alcohol as a white foam in 90% yield. m/z(M+H)+ 616.20 Step 11 : Methyl 2-[1-benzhydrylchloro-2—(hydroxyethy|)-1H-indolyl]ethy|}- yl)phenyl] propanoate (Step 10, 1 eq) in CH2CI2 (0.02 M) was treated at 0 °C with Me802C| (2.0 eq) and Et3N (2.5 eq) and stirred for 1 hour. The ice-bath was removed and the reaction mixture was stirred for 1 hour at room temperature before it was diluted with CH2CI2, washed with NaHzPO4, brine and dried over Na2SO4. Evaporation of the solvent afforded the te in quantitative yield. m/z(M+H)+ 695.0 Step 12: Methyl 3-(4-{[2-(1—benzhydry|ch|oro{2-[(methylsu|fonyl)oxy]ethyl}-1H- indol- 3-y|)ethy|]sulfony|}phenyl)propanoate (Step 11 in DMF , 1.0 eq) was dissolved (0.03 M) and treated with NaN3 (3.0 eq). The resulting mixture was heated to 60 °C and stirred for 2 hours, then cooled to room ature, diluted with water, extracted with ethyl acetate, washed with brine and dried with . Evaporation of solvent afforded the azide in quantitative yield, m/z (M+H)+ 641.1 Step 13: Methyl {2-[2-(2-azidoethyl)benzhydry|ch|oro-1H-indolyl]ethyl} yl)phenyl]propanoate (Step 12, 1 eq) was dissolved in THF (0.1 M), and treated with triphenylphosphine (1.1 eq). After 2 days water was added, and the mixture was stirred overnight, concentrated, and purified by flash chromatography using 4% MeOH:CH2C|2 as eluent to give the amine in 71 % yield. m/z(M+H)+ 615.2 Step 14: To a suspension of (2-trifluoromethylphenyl)methanesulfonic acid (20.3 g, 84 mmol) in THF (1.9 L) and DMF (5.0 mL) at —20 °C was added oxalyl chloride (44.7 mL,0.5 mol) slowly dropwise over 1hr. The bath temperature was maintained below 0 °C for 4 h, at which point the reaction was evaporated to a volume of ~ 250 mL and diluted with 500mL of ethyl acetate. This solution was washed with brine in a separatory funnel and dried over magnesium sulfate. The solution was then evaporated to a brown oil. This oil was taken up in 500mL of pet ether (30-50°) and heated with a heat gun until the oil went into on. The solution was then placed into a dry-ice acetone bath to cool resulting in formation of a white crystalline al. This material was collected via filtration and dried to afford 19 g (85%) of fluoromethylphenyl)methanesulfonyl chloride as a white solid.
Step 15: To ethyl 3-[4-({2-[2-(2-aminoethyl)benzhydryl- 5-chloro-1H-indoI—3- yl]ethyl}su|fony|)phenyl]propanoate (Step 14, 200 mg, 0.32 mmol) and sat. NaHCO3 (0.14 M) in CH2C|2 (0.07 M) was added (2-trifluoromethylpheny|)methanesulfonyl de (Step 14, 110 mg, 0.42 mmol). After 16 h the mixture was poured into ted sodium bicarbonate and extracted with CH2C|2. The combined organic phase was washed with brine, dried over sodium sulphate and purified by column tography to afford 250 mg of the sulfonamide, a pale yellow foam, in 93% yield. 1HNMR (400 MHz, CDCI3) 6 1.23 (t, J=I.2 Hz, 3 H), 2.62 - 2.71 (m, 2 H), 2.76 - 2.93 (m, 4 H), 2.98 — 3.17 (m, 4 H), 3.27 — 3.38 (m, 2 H), 4.11 (q, J=7.2 Hz, 2 H), 4.35 (s, 2 H), 4.57 (t, J=5.3 Hz, 1 H), 6.43 (cl, J=9.1 Hz, 1 H), 6.77 (dd, J=8.8, 2.0 Hz, 1 H), 6.81 (s, 1 H), 7.18 (cl, J=2.0 Hz, 1 H), 7.24 - 7.35 (m, 10 H), 7.41 (d, J=8.6 Hz, 3 H), 7.49 (t, J=8.3 Hz, 1 H), 7.60 - 7.77 (m, 2 H), 7.88 (cl, J=8.6 Hz, 2 H).
Step 16: The resulting sulfonamide ester (220 mg, 0.26 mmol) was yzed by stirring with 1N NaOH (5 equiv) in THF (0.07M) and enough MeOH to produce a clear on. The reaction was monitored by TLC (10% MeOH-CH2CI2) for the disappearance of starting material. When the reaction was complete, mixture was concentrated, diluted with H20, and acidified to pH 2-4 using 1M HCI. The aqueous phase was extracted with EtOAc and the organic phase was washed with brine, dried over sodium sulphate, and concentrated to afford 200 mg (92%) of 3-{4-[2-{5-chloro(diphenylmethyl)[2- ({[2—(trifluoromethyl)benzyl]sulfony|}amino)ethy|]—1H-indol—3- y|}ethyl]sulfony|}pheny|}propanoic acid, a white foam. 1H NMR (400 MHz, DMSO-ds) 6 2.65 (t, J=7.6 Hz, 2 H), 2.91 - 3.13 (m, 8 H), 3.60 (dd, J=9.7, 5.4 H21 2 H), 4.46 (s, 2 H), 6.48 (d, J=8.8 Hz, 1 H), 6.83 (dd, J=8.7, 2.1 Hz, 1 H), 7.05 - 7.16 (m, 5 H), 7.19 (d, J=2.3 Hz, 1 H), 7.33 - 7.47 (m, 6 H), 7.53 - 7.72 (m, 6 H), 7.80 (d, J=7.6 Hz, 1 H), 7.94 (d, J=8.3 Hz, 2 H), 12.26 (s, 1 H); HRMS: calcd for C42H33C|F3N20582 + H+, 823.18847; found (ESI—FTMS, [M+H]1+), 823.1887; HPLC purity H20/CH3CN: 100 %, HzoMeOH: 100 %.
Example 2 ‘Proof of concept’ in vitro drug tion and penetration experiment Commonly, in vitro skin permeation experiments involve the use of a diffusion cell designed to mimic the physiological and anatomical conditions of skin in situ. The model used in this ment was the Franz diffusion cell n et al. Topical and Transdermal Drug Delivery 2012: 85-100, Benson and Watkinson (Eds), incorporated herein by reference). Skin prepared as described below was positioned between the two halves of the cell with the Stratum corneum facing the donor compartment allowing for drug application. The aim of the work was to compare the drug concentrations permeating into and across dermatomed human skin when applied from different formulations/solvent systems. Where possible, the method was performed in ance to OECD 428 guidelines.
Skin preparation Human skin from cosmetic reduction surgery was used. Subcutaneous fat was removed ically and the skin was dermatomed to a thickness of 400 i 100 um using a Nouvag cutter.
Small scale skin permeation investigation The feasibility experiment was performed as follows: Preparation of the Franz cells (i) Franz diffusion cells, with an average surface area of approximately 0.6 cm2 and a volume of approximately 2.0 mL were employed. (ii) Skin (prepared as described above) was mounted between the donor and receiver compartments and the cells were sealed together using Parafilm and clips. (iii) To check the skin integrity the donor and receiver chambers were filled with PBS solution red by dissolving 1 PBS tablet in 100 mL of water) and a small magnetic follower was placed in the receiver compartment. (iv) Cells were brated in a waterbath ensuring a membrane temperature of 32 0C for 30 min (waterbath temperature of 37 oC).
(V) The resistance of the skin in each Franz cell was measured using the LCR 6401 idge.
(Vi) The electrodes were placed in the receiver compartment through the sampling arm and the donor chamber. (vii) The LCR was set at 100 Hz and set to ‘R’ for resistance. (viii) Cells with a resistance below the acceptable limits were discarded and remounted. Acceptable limits are defined ing to the ement of controls for dermatomed skin, where the skin has been deliberately bed.
Cells with greater than twice the resistance (KQ) of the control were considered acceptable and selected for the Franz ce|| permeation experiment. (ix) ing skin integrity testing the receiver compartment of acceptable cells was filled with receiver fluid. Each cell was then equilibrated to ensure a surface temperature of 32 °C (external skin surface temperature) for at least 30 min prior to closing (waterbath temperature of 37 0C). 00 An additional Franz cell (per skin donor) was also mounted but not closed (to act as a blank) to assess interference with sample quantification.
Dosing of test solvent s and sampling procedure Two solvent systems were selected for a small scale in vitro drug permeation study and was closed as described below: (i) The cells were assembled as bed above. (ii) Nine cells were assembled. Two solvent system (n=3), respective placebo t system (n=1) and a blank cell (n=1) were ed during the ility experiment. (iii) The selected solvent systems (6 mg) were applied directly to the surface of the skin with a positive displacement pipette (resulting in a dose of imately mg/cmz). The pipette was verified for the amount dispensed prior to closing to ensure reproducibility of dose. The verification of the amount dispensed was performed by weighing 6 replicates into a glass vial. Weights and volumes applied (to ensure a 6 mg dose) were recorded. (iV) Receiver fluid (200 uL) was d at the following time points t=0, 1, 2, 4, 6, 24, 30 and 48 h. Each sample was split into 2 x LCMS vials (100 uL per vial) where one was spiked with internal standard (1:1) and analysed using LC- MS/MS. The second vial was stored at -20 °C as a back-up.
Fresh pre-warmed receiver fluid (200 uL) was used to e the receiver fluid removed at each time point.
(Vi) Following the 48 h time point, Compound I was recovered from the Franz cell as described below.
Penetration investigation Following completion of the permeation experiment, quantification of al Compound I from the donor chamber, on the surface of the skin, Stratum corneum, epidermis and partial dermis was performed using the following procedure: Recovery from donor chamber 0) Three cotton swabs were used to recover Compound I from the donor chamber. (ii) After dismantling the Franz cell one of the dry cotton wool swabs was used to remove all residual solvent from all the internal surfaces of the donor chamber and the swab placed into a 7 mL vial. (iii) A second swab was then immersed into the extraction fluid and then used to swab the internal surface of the Franz cell, this swab was then placed into the vial containing the first swab. (iv) The final swab was used dry to swab the inside of the Franz cell and then placed into the glass vial containing the two other swabs.
(V) Using a pipette 2 mL of extraction fluid was added to the glass vial containing the cotton swabs.
(Vi) The vials were shaken on an orbital shaker at ambient ature for 16-20 h. (vii) Following the extraction procedure, the extraction solvent system was d from the vials and centrifuged at 13,000 RPM (16,060 g-force) for 10 min using a Heraeus Labofuge pico centrifuge to remove un-dissolved materials and particulates. (viii) The supernatant was split into 2 aliquots (100 pL in vial one and the der in the second vial), where vial one was spiked with internal standard (1:1) and analysed using LC-MS/MS. The second vial was stored at —20 °C as a p Recovery from upper surface of the skin 0) Three cotton swabs were used to recover Compound I from the surface of the skin. (ii) After dismantling the donor chamber from the Franz cell one of the dry cotton wool swabs was used to remove all of the residue solvent from the surface of the skin and the swab placed into a 7 mL vial. (iii) A second swab was then immersed into the extraction solvent and used to swab the surface of the skin, this swab was then placed into the vial ning the wash solvent and the first swab. (iV) The final swab was used dry to swab the surface of the skin and then placed into the glass vial containing the two other swabs. (v) An initial tape strip from the surface of the skin was also placed in with the cotton wool swabs from Step (iv) (vi) Steps (v) — (viii) from the method for recovery from the donor chamber were performed to complete the recovery of Compound I from the surface of the skin.
Recovery from the Stratum corneum (i) Up to 5 tapes strips were removed from the e of the skin to te the Stratum corneum from the epidermis and were placed in a 7 mL vial. (ii) Steps (v) — (viii) from the method for recovery from the donor chamber were performed to te the recovery of Compound I from the Stratum corneum.
Method for separation and recovery from epidermal membrane and partial dermis The remaining epidermis and partial dermis was processed as follows: (i) The epidermis and dermis were placed into an incubator at 60 °C for 2 min. (ii) The epidermis and dermis were then removed from the incubator and manually separated using gloved hands. (iii) The mal and dermal layers were placed into individual Precellys 24 homogeniser vials and 1 mL of extraction solvent was added. (iv) The Precellys vial from Step (iii) was placed in the Precellys 24 and the ts homogenised at 5,800 RPM for 2 x 20 s at 2-8 0C. (v) The contents of the Precellys vial from Step (iv) were emptied into a 7 mL glass vial. (vi) Extraction diluent (1 mL) were added to the empty Precellys vial from Step (v) and the vial vortex mixed for ca. 30 s, the contents were then emptied into the glass vial from Step (v). (vii) Steps (vi) — (viii) from the method for ry from the donor chamber were performed to complete the recovery of nd I from the epidermis and dermis.
FulI scale permeation and penetration study The full scale in vitro drug permeation and penetration experiment was performed as described in on to the small scale experiments, with the following modifications: (i) Two solvent systems, with Compound I at close to saturation, were investigated: one with ation enhancers (n=4 active, n=1 placebo) and one without penetration enhancers (n=4 active, n=1 placebo) (ii) Skin from 3 donors was used, Le. a total of 33 cells (n=12 cells per active, n=3 cells per placebo per formulation and n=3 cell as a blank per skin donor).
Data analysis The data analysis and statistical comparison of samples generated during the in vitro skin permeation experiment was performed as follows: (i) The concentration (ng/mL) of Compound I ed in each sample was quantified from the calibration standards analysed at the same time on the LC- MS/MS. (ii) The total amount (ng) of Compound I per volume sampled was calculated (total amount/volume sampled = ng/mL x volume sampled). (iii) The total amount (ng) of Compound I recovered at each time point was then calculated (total amount = ng/mL x total volume of each Franz cell). (iv) The cumulative amount (ng) of Compound I was calculated by adding the total amount (ng, Step (iii)) at each time point with the total amount awn (ng) from each of the us time points (Step (ii)). (v) The cumulative amount per unit area of Compound I (ng/cm2) was calculated by dividing the cumulative amount (ng, Step (M) by the diffusion area (ng/cm2 = cumulative amount (ng) / diffusion area). (vi) Any outliers were rejected ing to internal ures, however all data were reported (vii) Flux rates (where possible) and penetration were calculated from the Compound I concentrations measured in the receiver fluid over time and concentration recovered from the dermis, tively.
Identification of outliers Suspected outliers in the permeation/penetration experiment were confirmed and eliminated from further data analysis if their permeation data exceeded the limits defined by the following: mean value + ndard deviation) < Outlier < mean value — (2*standard deviation) Statistical analysis Statistical analysis of the permeation and recovery data from the donor, surface, Stratum corneum, epidermis, dermis and receiver fluid was performed using SPSS. The recovery data was analysed to confirm whether the variance of each group was equal using the Levene‘s test. If the data was of equal or unequal ce, the determined p value is either p > 0.05 or p s 0.05, respectively. Subsequently, an independent T-test was used assuming equal (i.e. p > 0.05) or unequal ce (i.e. p < 0.05) and the statistical comparison was performed for the amount of Compound I recovered from the skin matrices. The comparison between the ry of Compound I from the m m, epidermis and dermis of the same formulations was ed for normality using the Shapiro-Wilk test to determine if the data was either parametric or nonparametric , where the determined p value was either p > 0.05 or p S 0.05, respectively.
If the data was parametric (i.e. normally distributed, p > 0.05 determined using the Shapiro-Wilk test) the statistical comparison was performed using a one way ANOVA Tukey’s HSD. However, if it was determined that the data was non-parametric (i.e. unequal variances p s 0.05 determined using the Shapiro-Wilk test) the tical comparison of the data was carried out using a one way ANOVA with Post Hoc Tamhane.
Results Small scale permeation/penetration experiment The small scale permeation experiment was conducted using the following procedure: . Compound I in PEG—400 ($81) and Compound I in PEG-400 (75 % w/w) and Transcutol P (25 % w/w) (552) were assessed, n=3 cells per t system using skin from a single donor (dermatomed human skin) . : ca. 6 mg (Le. 10 mg/cmz) . EtOH (20 % v/v) in water was used as the er fluid . er fluid samples were taken at t=0, 1, 2, 4, 6, 24, 30 and 48 h. Two sample volumes were investigated due to the low solubility of Compound I in potential receiver fluids; 200 uL and 1.5 mL.
. Following the final time point Compound I was recovered from the donor compartment, surface, Stratum corneum, epidermis and dermis using tissue homogenisation and solvent extraction (diluent: 90:10, EtOH:water).
The small scale experiment was used to confirm the protocol for the full scale permeation/penetration experiment. nd I was not detected in the receiver fluid over the duration of the 48 h ment irrespective of sample volume.
The values for the recovery of Compound I following the application of t systems 881 and 552 are illustrated in Figure 1 with the amount recovered from the surface removed in Figure 2 for ease of data interpretation. For each solvent system applied the total recovery of Compound I ranged from 90.00 — 109.72 % of the applied close. The t amount of Compound I was recovered from the solvent system remaining on the e. Compound I was also recovered from the Stratum corneum, epidermis and dermis in similar amounts.
Full scale in vitro permeation and penetration ment The permeation and penetration of Compound I from two solvent systems was assessed using abdominal skin from three skin donors. The mean cumulative amount (ng/cmz) of Compound I permeated following the application of the solvent systems h dermatomed skin was plotted t time (h). The solvent systems were: Compound I in PEG-400 (F881) and Compound I in PEG-400 (60 % w/w), Arlasolve DMI (15 % w/w) and Transcutol P (25 % w/w) (FSSZ). The amount of Compound I (ng, mean + SEM) from the donor, surface, Stratum m, epidermis, dermis and receiver fluid were presented from all three skin donors.
The in vitro permeation of Compound I from the two solvent systems (F881 and F882), across dermatomed nal skin from three donors over a 48 h experimental period is illustrated in Figure 3. Permeation of Compound I was observed at low levels from both solvent systems over the 24 h mental period with Compound I which was first detected in the receiver fluid after 1 h post application of the solvent systems (F881 and F882). The permeation profiles of Compound I for both solvent systems followed a r trend with Compound I present in the receiver fluid at t=1 h followed by a plateau, the decrease towards the end of the e was within error and t to be a result of the low levels of Compound I being quantified and donor to donor variability.
Despite the low levels of Compound I detected in the er fluid the permeation of Compound I following application of FSSl was observed to be significantly higher (p < 0.05) than the permeation of Compound I following the application of FSSZ. The in vitro penetration of Compound I from the solvent systems (F551 and F882), across dermatomed abdominal skin from three donors is illustrated in Figures 4 and 5. The recovery of Compound I following the final time point was observed to be 101.47 0/o and 87.39 % of the applied close for solvent systems F881 and F882, respectively.
Compound I was recovered in the highest amounts from the surface of the skin following the application of F881 and F882, were between ca. 82 % (FFSZ) — ca. 97 0/o (FSSl) of the d close was recovered.
For ease of data retation the amount of Compound I recovered from the e has been removed in Figure 5 to highlight the recovery of Compound I from the Stratum corneum, epidermis, dermis and receiver fluid n the solvent systems (F551 and F882). The amount of Compound I recovered following the application of FSSl was highest (based on mean amounts) in the epidermis (3281 i 1435 ng) > Stratum corneum (1976 i 729 ng) > dermis (1593 i 609 ng) > er fluid (4.67 i 0.58 ng).
The amount of Compound I recovered from the skin layers and receiver fluid following the application of FSSZ was lower (although no significant difference was observed n the skin layers, p > 0.05, the receiver amount of Compound I recovered from the receiver fluid was significantly lower (p < 0.05)) than the amount recovered following the ation of FSSl. The rank order of Compound I recovered from the skin matrices was different to that observed with FSSl with the highest amount (based on average amount) of Compound I recovered from the dermis (1126 i 543 ng) > Stratum corneum (931 i 310 ng) > epidermis (352 i 113 ng) > receiver fluid (0.89 i 0.27 ng).
However, the difference in rank order was not considered an issue, as the levels recovered in the Stratum corneum, epidermis and dermis were not icantly different (p > 0.05) for each t system.
The approximate concentration of Compound I within the epidermis and dermis was calculated using the ing procedure: a. The thickness of the epidermis and partial dermis were d to be between 30- 130 and 250-350 pm, respectively (a range of skin thickness were used to provide the best and worst case scenario for the level of Compound I detected in the epidermis). b. The area of the skin used was ca. 0.6 cm2 and therefore the volume of the epidermis and partial dermis were 0.0018-0.0078 and 0.015-0.021 cm3, respectively. c. Assuming the density of the skin is 1 and that 1 cm3 = 1 g the weight of the epidermis and partial dermis would be 0.0018-0.0078 and 0015-0021 g, respectively. d. The total amount of Compound I recovered from the epidermis and partial dermis were then divided by the mass to obtain and approximate amount (ng/g) of Compound I recovered. e. The amount recovered (ng/g) was subsequently divided by the molecular weight (823.34 Da) to provide a concentration in nanomoles/g which was subsequently converted to micromoles/kg (micromolality) of Compound I recovered from the mis and dermis (equivalent to micromolarity (umol/L; uM) when assuming the density of the skin is 1 g/cm3).
The results of the calculation are ised in Table 2. nd I is a sub-low nanomolar inhibitor of cPLA2cx ty in ar and enzymatic assays. The trations ed in the epidermis and dermis is indicative that they are sufficient to significantly inhibit cPLA20c biological activity at these sites.
Table 2. Concentration range of Compound I (uM) in the epidermis and dermis (based on average amounts and a range of skin ess) following ation of F881 and F882 at the 48 h time point. Values represent a range based on skin thickness and e amount recovered, n=9—10.
Skin layer ‘ Average concentration (uM) l F881 F882 Epidermis l 511 - 2214 55 - 238 Dermis l 92 - 129 65— 91 Example 3 — Effect on PMA-induced inflammation in mice Phorbol 12-myristate 13-acetate (PMA) is commonly used to induce mation and oedema of the skin of laboratory animals as a preclinical inflammation model.
In the present example PMA was dissolved in a 10% ethanol solution to a final concentration of 0.4 pg per pl. A 10 pl was applied to the ears of Balb/C laboratory mice 1 hour after topical application of 3-{4-[2-{5-chloro(diphenylmethyl)[2-({[2- (trifluoromethyl)benzyl]sulfonyl}amino)ethyl]—1H-indol y|}ethyl]sulfony|}pheny|}propanoic acid (Compound I) in a 10% ethanol solution at either 0.3 0/o or 3 0/o w/w. As a negative control the vehicle was applied without the active compound. Positive controls were indomethacin (a non-steroidal anti- inflammatory drug) and CAY10650 (a known CPLAzot inhibitor).
The level of oedema was monitored by measurement of ear thickness by calliper at intervals of 1, 3, 6 and 24 hours Figure 6 shows the change in ear thickness over time (in hours after PMA application) for different doses of3-{4-[2-{5-chloro-1—(diphenylmethyl)[2-({[2- (trifluoromethyl)benzyl]sulfony|}amino)ethyl]-1H-indol yl}ethyl]su|fony|}pheny|}propanoic acid (Referenced as Compound I).
Figure 7 shows a comparison of 3-{4-[2-{5-chloro—1-(diphenylmethyl)[2-({[2- (trifluoromethyl)benzyl]sulfony|}amino)ethyl]-1H-indol y|}ethy|]su|fony|}phenyl}propanoic acid (Referenced as Compound I) with other compounds.
Topically applied 3-{4-[2-{5-chloro(diphenylmethyl)-2—[2-({[2- (trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol yl]sulfonyl}pheny|}propanoic acid was found to show dose-dependent reduction in PMA-mediated skin oedema with efficacy comparable to orally-dosed indomethacin.
This demonstrates that the drug is effective in vivo when administered topically.
Example 4 — Preparation of PEG based ointments Several ointments as described in Table 3 were prepared according to the following procedure: (i) PEG-400 was weighed into a suitably sized glass container. (ii) The Compound I was weighed (where applicable) into a weigh boat and then erred into the system from Step (i) and stirred until complete dissolution was observed. (iii) The following excipients (where applicable), propylene glycol, ethanol, water and glycerol were tially weighed into the container from Step (ii), a magnetic follower was inserted and the contents d until the solution was observed to be visually homogenous. (iv) PEG 400 was d into a separate suitably sized glass container and heated in a water bath previously calibrated at 65 0C. (v) PEG 400 was stirred until a clear melt was ed at which point it was added to the solvent system (step (iii)) which had been heated to 61 oC. (vi) The formulation (step (iv)) was stirred until visually mixed and then removed from the water bath. (vii) The ation was mixed until it reached ambient temperature.
W0 2015/118320 Table 3. Composition (% w/w) of ointment formulations Composition (% w/w) SE?" To?)— PG Ethanol Water Glycerol 2:36 comfiound TOTAL 02 69.9 5.1 0 5 0 17 3 100 02X 69.9 5.1 0 0 5 17 3 100 O4 50 19 0 5 5 20 1 100 O4v4 52.5 16.5 0 5 5 20 1 100 O4v4E 52.5 16.5 5 5 0 20 1 100 05v2 45 25 0 10 0 19.7 0.3 100 05v2E 45 25 5 5 0 19.7 0.3 100 05X 45 25 0 0 10 19.7 0.3 100 05EX 45 25 5 0 5 19.7 0.3 100 07 59.9 0 10 5 5.1 17 3 100 08 59.9 5 10 0 5.1 17 3 100 Example 5 — Preparation of cream and lotion formulations Cream and lotion formulations as described in Tables 4, 5 and 6 were prepared as described below: (i) PEG-400 was weighed into a suitably sized glass container. (ii) Compound I was weighed (where applicable) into a weigh boat and then transferred into the system from Step (i) and stirred overnight. (iii) The remaining aqueous phase excipients were weighed into a container from Step (ii) and the contents stirred. (iv) The gelling agent (if able) was added to the vial from Step (iii) and homogenised for 30 s or until the complete dispersion of the gelling agent was observed. (v) In a separate ly sized glass ner the 0" phase excipients were weighed and the oil phase heated in a water bath usly calibrated at 65 oC. (vi) The oil phase was stirred until a clear melt was observed. (vii) When a clear melt of the oil phase from Step (iii) was observed the s phase from Step (v) was preheated for a maximum of 5 min in a water bath previously calibrated at 61 °C. (viii) The oil phase was slowly transferred into the aqueous phase and the formulation from Step (vii) was homogenised on the m speed setting (10,000 RPM) for 2 min. Prior to homogenising the formulation the homogeniser head was pre- warmed. (ix) The formulation was then stirred by hand until it had cooled to room temperature.
Table 4: Example Tween/Span Creams Composition (% w/w) Excipient Tween/Span Tween/Span Tween/Span cream 1 cream 2 cream 4 Ethanol 5 - 5 Water 19.7 19.7 11.5 PEG-400 36 41 43.5 Transcutol P 15 - 15 Arlasolve DMI Benzyl alcohol 2 2 2 Phenoxyethanol - - - Carbopol 980 - - - Tween 60 5 5 5 Span 60 2 2 2 White soft paraffin - - - Liquid paraffin - - - earyl alcohol 5 5 5 crogol 1000 - - - Crodamol GTCC 10 10 10 Compound I 0.3 0.3 1 TOTAL 100 100 100 Emeu de mAmv ma EmeU WMH mm mH HHmUDKDKON m.o ooH Emeu WMH mm mH HLDOOKOKON m.o ooH SE 0Emeu Ada Nam wé m.o ooH :oEmOQEou vEmmLU mdfi md GDKOKON OCH E85 OH OH NH OCH mcosmSELou. 885 h.mH mm ma eomomeBwuv Emwhu "OH OOkDKON m.o OOH F696 memem oooH n. owm :E98 _o;8_m H_>_fl_ _ocou_m UUPQ H om t8 Steam 2an EmEUxm 692%. L885 ooTDmE _8:umcE._. _._< _>N:wm_ _ocm£w>xocwcn_ _0n_0n_\_mU :wwzF 823 2%: 3.88850 BaomeBmU _oEm_uo\_U ucsogEoU 43.0% 2015/050299 might»: w:032 NOH mN.Nm 3 N m.O - m - m - N mnO m.O OOH mzw\.r>_>_ nco_uo_ ON mnqm 3 N m.O - - m m - N mnO O OOH -omeBwU O c030. ON mam 3 N m.O H - m m mg - - - - O OOH 9:2 :032 :wwzc. m ON mv 3 N - - - m N - m N - - O OOH £3 saw 835888 \ :032 :wmzc. v ON 9. B N - - - m m - m N - - O OOH -omeBwU m :32 de Eu 3 N - - mdfi - m NA - - - - O OOH -omeBwU N :052 DE Eu 3 N - - m.mH - NR mg - - - - O OOH mcoDmSE‘é -omeBwU H :25 DE Eu 3 N - v md - NR mg - - - - O OOH c032 m_n_mem OOOH SE :E98 _o;ou_m _or_ou_< owm cEEmQ 00.5 H t8 OO Ovm 222. EwEUxm L825 OO¢-wm_n_ w>_omm_._< _>N:mm_ 689.8 8.2; USU: _oEmuoLu 358860 _oOo._umE8.mu 52:. :96 E2 920 choquu ._<._.O._.
Example 6 — Preparation of gel ations Several gel formulations as described in Table 7 were prepared as follows: Gel formulations (i) PEG-400 was d into a suitably sized glass container. (ii) Compound I was weighed (where applicable) into a weigh boat and then erred into the system from Step (i) and stirred until te dissolution was observed. (iii) The following excipients (ethanol, water, propylene glycol, Transcutol P, Arlasolve DMI, benzyl alcohol and phenoxyethanol, where applicable) were sequentially weighed into a the glass vial from Step (ii). (iv) A magnetic follower was inserted into the vial from Step (iii) and the ts of the vial were stirred until visually nous.
The gelling agent (HPC/ Carbopol 980) was weighed into a weigh boat and transferred slowly (mitigating the risk of agglomeration of the gelling agent) to the vial from Step (iv) under constant ng.
(Vi) For Carbopol based gels the pH was checked to ensure it was ca. pH 6, where no pH adjustment would be required. (vii) The formulations were stirred until complete ion of the gelling agent was observed.
Emulsified gel formulations (i) PEG-400 was weighed into a suitably sized glass container. (ii) Compound I was weighed (where applicable) into a weigh boat and then transferred into the system from Step (i) and stirred until complete dissolution was observed. (iii) The following excipients (ethanol, water, propylene glycol, Transcutol P, Arlasolve DMI, benzyl alcohol, phenoxyethanol and poloxamer 407, where applicable) were sequentially weighed into the glass vial from Step (ii). (iv) A magnetic follower was inserted into the vial from Step (iii) and the contents of the vial were stirred until visually homogenous.
(V) The gelling agent pol 980) was weighed into a weigh boat and transferred slowly (mitigating the risk of eration formation) to the vial from Step (iv) under constant stirring.
(Vi) The pH was checked to ensure it was ca. pH 6, where no pH adjustment would be required. (vii) Cyclomethicone was weighed into the glass vial from Step (v) and the system was nised for 2 min at 10,000 RPM until complete dispersion of the cyclomethicone was observed. (viii) The formulations were subsequently stirred until complete hydration of the gelling agent was observed.
WO 18320 TWAL 02 8H 02 8H 9: 2: 8H ooH 8H 9: 8H 2: CmWu.m I m m m m m m H H H H H H CmWm %0 - N H mH - mH m.H mH mH H H N HW H F N - - - m.H - - - - - - - %.mmeMO7 - - - - - - - - - H H H NM - - - - - - - - - mH - - Wmmtmne - - - - - - - - - - mH mH mmWamnalU - - - - - - - H - - - - BmW, a.anO I N N N N N N N - N N N N AmAlvue DM I - - - - mH 2 mH mH mH - - - Tmmw.d P NN NN NN NN - - mN N N mH mH mH PG - - - - - - - 2 3 m m m m m m EGA.m Hm Hm Nm mHm mm mm WON DR 3N . . . ow ow ow mcorerEouH m m mm oH oH OH oH no no. mH 2 mH . . mN r HH HH .
Emnd oH oH 2 OH 3 2 oH - - 2 2 OH mEmem H H Ewafixm A235 888 $88 mm 60 60 o\0v H H 888%; N>H v Swmgmé 898va man <9 2an mm am aw am we am am aw mm 8:535 2):: SEEM AmcouEumEoUBv BEmSEm N>H While the ion has been described in detail and with reference to specific ments thereof, it will be apparent to one of skill in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof. Moreover, all embodiments described herein are considered to be broadly applicable and combinable with any and all other consistent embodiments, as appropriate.
Claims (15)
1. A pharmaceutical composition for topical administration comprising n 0.01% and 10% (w/w) of a compound of formula I: or a ceutically acceptable salt thereof, wherein the composition is in a form for topical administration, and wherein the composition comprises a solvent, a co-solvent, a penetration enhancer, and water.
2. The pharmaceutical composition of claim 1, wherein the compound of formula I or pharmaceutically acceptable salt thereof is present at from 0.3% to 3% (w/w).
3. The pharmaceutical ition of claim 1, wherein the compound of formula I or pharmaceutically acceptable salt thereof is present at 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10% (w/w).
4. The pharmaceutical composition of any one of claims 1-3, wherein the composition is in a form selected from ointments, gels, , lotions, oil-in-water emulsions, water-in-oil emulsions, microemulsions, foams, sprays, mousses, patches, powders, pastes, and ted plasters.
5. The pharmaceutical composition of any one of claims 1-4, wherein the composition is in the form of an ointment that comprises 69.9 % (w/w) PEG-400, 5.1 % (w/w) propylene glycol, 5% (w/w) water, 17% (w/w) PEG-4000, and 3% (w/w) of the compound of formula I.
6. The ceutical ition of any one of claims 1-4 n the composition is in the form of an ointment that comprises 59.9 % (w/w) PEG-400, 10% (w/w) ethanol, 5% (w/w) water, 5.1 % (w/w) glycerol, 17% (w/w) PEG-4000, and 3% (w/w) of the compound of formula I.
7. The pharmaceutical composition of any one of claims 1-4, wherein the composition further comprises an additional therapeutic agent.
8. The pharmaceutical composition of any one of claims 1-4, further sing an emulsifier.
9. The pharmaceutical composition of any one of claims 1-4, further comprising a viscosity-increasing agent.
10. Use of a pharmaceutical ition ing to any one of claims 1-9 in the manufacture of a medicament for the treatment of a dermal inflammatory disease or a dermal inflammatory condition.
11. The use of claim 10, wherein the dermal inflammatory e or dermal matory condition is a cytosolic phospholipase pendent or cytosolic phospholipase A2a-mediated disease or condition.
12. The use of claim 10, wherein the dermal inflammatory disease or dermal inflammatory condition is selected from the group comprising scarring, itis, a proliferative disease or condition, a mast cell disease or condition, a burn or contact with an allergen and/or an irritant.
13. The use of claim 10, wherein the dermal inflammatory disease or dermal inflammatory condition is selected from the group comprising atopic dermatitis, bullous disorders, collagenoses, psoriasis, tic lesions, seborrheic dermatitis or contact dermatitis, eczema, urticaria, pruritus, rosacea, prurigo nodularis, rophic scarring, keloid scar formation, scleroderma, Folliculitis keloidalis nuchae, Kawasaki Disease, Sjogren-Larsson Syndrome, Grover's disease, a first degree burn, a second degree burn, a third degree burn, a fourth degree burn, cutaneous mucinosis, solar keratosis, squamous cell carcinoma or melanoma, asteatotic , discoid eczema, hand eczema, gravitational/varicose eczema, eczematous drug eruptions, lichen simplex, lichen sclerosus, lichen planus Irritant, allergic contact itis, llergic/photoaggravated dermatitis, infective (secondary to bacterial/viral/fungal infection) dermatitis, ic diseases including those associated with c systemic disorders such as uremic pruritus, cholestatic pruritus, adult blaschkitis, aquadynia, aquagenic pruritus, balsam of Peru, biliary pruritus, brachioradial pruritus, druginduced pruritus, hydroxyethyl starch-induced pruritus, itchy points, lichen simplex chronicus, ermatitis, prion pruritus, prurigo, prurigo tosa, prurigo simplex, pruritus ani, pruritus scroti, pruritus , puncta pruritica, referred itch, renal pruritus, scalp pruritus, senile pruritus, xerotic eczema, itch associated with HIV infection, T-cell lymphoma, Sezary syndrome and mycosis fungoides.
14. The use of claim 10, wherein the dermal inflammatory disease or dermal inflammatory condition is selected from atopic dermatitis and psoriasis.
15. Use of a pharmaceutical composition according to any one of claims 1-9 in the manufacture of a medicament for treating inflammation or oedema in a patient in need thereof. ZIARCO PHARMA LTD By the Attorneys for the Applicant SPRUSON & FERGUSON Per: 2015/050299 Donor Surface S.corneum Epidermis Dermis RF flg@ Ela [m] volume 882 mL) (sample 5 W1 WWW g volume LL (sample 200 volume uL) 881 (sample 200 700000 600000 500000 400000 300000 200000 100000 0 (Bu) peJeroeJ | punoduJoo ;o lunOUJV Donor S.comeum Epidermis Dermis IQ El VA E mW_. WWW"V'o'o'ovvv'ovowvovowzvgggé a %_ LOrII N 9 E kA0A0A0A0M0A0A0A0Am0A0A0A0A0000 00000004mmm«mazwzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzg g ‘— k (I) \\\\\\\\\\\\\\\\\\\\Nm, 3 A o
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1401904.6 | 2014-02-04 | ||
GB201401904A GB201401904D0 (en) | 2014-02-04 | 2014-02-04 | Pharmaceutical composition for topical administration |
PCT/GB2015/050299 WO2015118320A1 (en) | 2014-02-04 | 2015-02-04 | Pharmaceutical composition for topical administration |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ722505A NZ722505A (en) | 2021-04-30 |
NZ722505B2 true NZ722505B2 (en) | 2021-08-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10034858B2 (en) | Pharmaceutical composition for topical administration | |
EP2200613B1 (en) | Phenazine derivatives and uses thereof | |
US10905683B2 (en) | Compositions and uses of amidine derivatives | |
US8378105B2 (en) | Crystalline pharmaceutical and methods of preparation and use thereof | |
US10450280B2 (en) | Tetrazolones as a carboxylic acid bioisosteres | |
US20090258069A1 (en) | Delivery of LFA-1 antagonists to the gastrointestinal system | |
US12005067B2 (en) | JAK inhibitor with a vitamin D analog for treatment of skin diseases | |
ES2928904T3 (en) | ROR-gamma modulators | |
KR20180094938A (en) | Combination of opioid receptor ligand and cytochrome P450 inhibitor | |
WO2019200224A1 (en) | Synergistic drug combinations predicted from genomic features and single-agent response profiles | |
US20230181746A1 (en) | Benzoylhydrazide-derived hdac degraders as therapeutics for treating cancer and other human diseases | |
NZ722505B2 (en) | Pharmaceutical composition for topical administration | |
JP2019504084A (en) | NRF2 activating compounds and uses thereof | |
US20210052603A1 (en) | Modulators of orphan nuclear receptors for nash and other metabolic disorders | |
US20100093725A1 (en) | Semi-solid formulations of phospholipase enzyme inhibitors | |
US11071731B2 (en) | Allosteric modulators of the mu opioid receptor | |
US10376515B2 (en) | Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activating enzyme ATG7 | |
US9775828B2 (en) | Pharmaceutical composition with increased solubility by using saccharin | |
US20190210973A1 (en) | Compounds and methods for treatment of cystic fibrosis | |
WO2007012967A2 (en) | Combination of voriconazole and fluconazole | |
KR20170088881A (en) | Pharmaceutical composition having bicyclic nitrogen-containing aromatic heterocyclic amide compound as active component |